HGS First Quarter Results Fair; Bigger News Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite others’ setbacks, firm maintains optimism for Phase III lupus drug.
You may also be interested in...
HGS Invests In Oncology As Phase III Drugs Near Submission
Human Genome Sciences targets 2010 for Albuferon and LymphoStat-B launches.
HGS Invests In Oncology As Phase III Drugs Near Submission
Human Genome Sciences targets 2010 for Albuferon and LymphoStat-B launches.
Rituxan For Lupus Misses Primary, Secondary Endpoints
Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.